BioAge Labs, Inc.·4

Mar 3, 4:44 PM ET

GOLDSTEIN DOV A MD 4

4 · BioAge Labs, Inc. · Filed Mar 3, 2026

Insider Transaction Report

Form 4
Period: 2026-03-01
GOLDSTEIN DOV A MD
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2026-03-01$4.38/sh+3,542$15,51433,033 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1]
    2026-03-013,542159,375 total
    Exercise: $4.38Exp: 2035-02-17Common Stock (3,542 underlying)
Footnotes (1)
  • [F1]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Signature
/s/ Dov A. Goldstein|2026-03-03

Documents

1 file
  • 4
    form4-03032026_090347.xmlPrimary